Daniel Cherqui, Alain Rahmouni, Frédéric Charlotte, Hatem Boulahdour, Michel Meignan, Pierre‐Louis Fagniez, Elie‐Serge Zafrani, Didier Mathieu, Daniel Dhumeaux, Jean‐Michel Métreau – 1 December 1995 – Preoperative distinction between focal nodular hyperplasia (FNH) that should be managed conservatively and hepatocellular adenoma (HA) that should be resected remains difficult. The result is controversial management of these patients.

Hideya Noguchi, Kenji Hirai, Yoshinori Aoki, Kenji Sakata, Kyuichi Tanikawa – 1 December 1995 – We performed a partial splenic arterial embolization in 22 patients with cirrhosis associated with thrombocy‐topenia and then evaluated the changes in platelet kinetics after undergoing the procedure using 111In‐tropolone–labeled platelets. The controls consisted of eight chronic hepatitis patients who showed a normal platelet count and normal spleen size. The mean splenic infarction ratio after the procedure was 54.9%.

Naokatu Arakaki, Shuichi Kawakami, Osamu Nakamura, Tomokazu Ohnishi, Hiroomi Miyazaki, Takehisa Ishii, Hirohito Tsubouchi, Yasushi Daikuhara – 1 December 1995 – Human hepatocyte growth factor (hHGF), which is now known to be the same protein as the scatter factor and the tumor cytotoxic factor, is a heterodimeric protein with one heavy chain and one light chain linked together by a disulfide bond, and is thought to be involved in liver regeneration.

Gerald Y. Minuk, Tony Gauthier, Xin K. Zhang, Gu Qi Wang, Norman M. Pettigrew, Frank J. Burczynski – 1 December 1995 – To determine whether the inhibitory effects of ethanol on hepatic regeneration could be prevented by ciprofloxacin, a fluroquinolone antibiotic with gammaaminobutyric acid (GABAA), receptor antagonist properties, adult, male Sprague‐Dawley rats (n = 6‐8/group) received intraperitoneal injections of saline, putrescine (a hepatic growth promotor, 50 mg/kg), or ciprofloxacin (100 mg/kg), followed 1 hour later by gastric gavage with saline or ethanol (5 g/kg).

Ernst Petzinger, Lutz Nickau, Jurgen A. Horz, Siegfried Schulz, Gunther Wess, Alfons Enhsen, Eugen Falk, Karl‐Heinz Baringhaus, Heiner Glombik, Axel Hoffmann, Stefan Müllner, Georg Neckermann, Werner Kramer – 1 December 1995 – To obtain prodrugs with affinity to liver parenchymal cells, the hepatic 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors HR 780 and lovastatin (syn. mevinolin) were conjugated with the bile acids cholic acid, taurocholic acid, and glycocholic acid.

Jurgen Ludwig, Gist H. Farr, Deborah K. Freese, Irmin Sternlieb – 1 December 1995

Thomas L. Treadwell – 1 December 1995

1 December 1995

Mohd R. Teli, Oliver F. W. James, Alastair D. Burt, Mark K. Bennett, Christopher P. Day – 1 December 1995 – Nonalcohol‐induced fatty liver is widely believed to be a benign condition with little or no risk of disease progression. There have been occasional reports of progression to cirrhosis but none in the absence of preexisting fibrosis on the index biopsy specimen even when co‐existing hepatitis was present (steatohepatitis). From our histological database (1978 to 1985), we identified 161 patients with fatty liver seen at our institution and traced the case notes of 156.

1 November 1995